BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 6690032)

  • 21. Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells.
    Yanovich S; Preston L; Shaw JM
    Cancer Res; 1984 Aug; 44(8):3377-82. PubMed ID: 6744272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
    Nori M; Gothoskar BP
    Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
    Hait WN; Pierson NR
    Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine.
    Jaffrézou JP; Levade T; Chatelain P; Laurent G
    Cancer Res; 1992 Dec; 52(23):6440-6. PubMed ID: 1423291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells.
    Ramu A; Glaubiger D; Magrath IT; Joshi A
    Cancer Res; 1983 Nov; 43(11):5533-7. PubMed ID: 6311408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells.
    Krishan A; Sauerteig A; Gordon K; Swinkin C
    Cancer Res; 1986 Apr; 46(4 Pt 1):1768-73. PubMed ID: 3948163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
    De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
    Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
    Chandrasekaran B; Dimling J; Capizzi RL
    Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ornithine decarboxylase--a predictor for tumor chemosensitivity.
    Bachrach U; Shayovitz A; Marom Y; Ramu A; Ramu N
    Cell Mol Biol (Noisy-le-grand); 1994 Nov; 40(7):957-64. PubMed ID: 7849562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characteristics of anthracycline-resistant strains of P388 leukemia].
    Goncharova SA; Demidova NS; Shiriaeva OA; Shevtsova VN; Konovalova NP
    Eksp Onkol; 1987; 9(4):42-7. PubMed ID: 3678124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
    Adwankar MK; Chitnis MP
    Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
    Ling YH; Priebe W; Perez-Soler R
    Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state.
    Pfeil D; Bergmann J; Fichtner I; Stein U; Hentschel M; Rothe I; Goan SR
    Anticancer Res; 1994; 14(2A):571-6. PubMed ID: 7912495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
    Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
    Wilkoff LJ; Dulmadge EA
    J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and biscoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells.
    Yamamoto S; Hui PZ; Fukuda Y; Tatsumi K; Mino M
    Biochem Int; 1989 Jun; 18(6):1077-83. PubMed ID: 2751676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
    Satyamoorthy K; Deshpande SS; Chitnis MP
    Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo characterization of P388 leukemia resistant to mitomycin C.
    Rose WC; Huftalen JB; Bradner WT; Schurig JE
    In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.